ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0662

Serum Urate Reduction Is Causally Associated with Flare Outcomes in People with Gout: Evidence for Surrogate Status from a Pooled Analysis of 2 Randomized Trials

Lisa Stamp1, Chris Frampton1, Melanie Morillon2, William Taylor3, Nicola Dalbeth4, Jasvinder Singh5, Micheal Doherty6, Weiya Zhang6, Helen Richardson6, Aliya Sarmanova7 and Robin Christensen8, 1University of Otago, Christchurch, Christchurch, New Zealand, 2Odense University Hospital, Odense, Denmark, 3University of Otago, Wellington, New Zealand, 4University of Auckland, Auckland, New Zealand, 5University of Alabama at Birmingham, Birmingham, AL, 6University of Nottingham, Nottingham, United Kingdom, 7University of Bristol Medical School, Bristol, United Kingdom, 8Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen & Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Copenhagen, Denmark

Meeting: ACR Convergence 2021

Keywords: Biomarkers, gout

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Session Title: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Use of serum urate (SU) as a treatment target and outcome measure has become controversial in light of the American College of Physician Gout Guidelines which advocated a “treat-to-symptom”, rather than a “treat-to-target SU” approach to management. The choice of SU as a treatment target measure implies that achievement of target SU is causally associated with improvement in patient-centered outcomes such as reduction in the number of gout flares. The aim of this study was to assess the causal relationship between achieving target SU and occurrence of gout flares.

Methods: Individual patient data from two randomized trials were analyzed to determine the relationship between SU and flares. Study one (Nottingham, UK) was a 2-year randomized trial comparing nurse-led and GP-led gout care (n=517) (1). Study two (New Zealand) was a 2-year open label randomized trial assessing the safety and efficacy of allopurinol dose escalation (2, 3). Individuals who on average achieved SU < 6mg/dL at 6, 9 and 12 months post-baseline were defined as “SU responders”. The primary endpoint was the proportion of participants having at least one gout flare from 12 to 24 months. The secondary endpoint was the actual number of flares from 12 to 24 months (collected as a number between 0 and 4 per month) and tophus regression. The individual patient data sets from New Zealand and Nottingham were combined and analyses undertaken for the primary and secondary outcome measures. These analyses were undertaken using the models as above with the addition of a fixed factor to account for New Zealand and randomization within the Nottingham dataset.

Results: Significantly fewer SU responders experienced a gout flare in months 12-24 compared to SU non-responders; unadjusted OR 0.20; 95%CI 0.15 to 0.29. In the Nottingham study, there was no effect of randomization on the relationship between serum urate response group and the presence or absence of gout flares (p=0.13) indicating that the reduction in SU is responsible for the absence of flares. The mean number of flares in months 12-24 was significantly lower in SU responders compared to SU non-responders, unadjusted mean difference -1.64; 95%CI -1.85 to -1.44. This association was also independent of the randomized treatment allocation. Combining the individual data for both NZ and Nottingham revealed those participants with a tophus at baseline, 38/55 (69.1%) of SU responders lost the sentinel tophus compared to 8/22 (36.4%) of the SU non-responders (OR 3.9; 95%CI 1.4 to >11.1).

Conclusion: We have shown using individual patient data from 2 RCTs that achieving an average SU < 6mg/dL over a 6-month period is likely causally associated with the subsequent absence of gout flares, a reduction in the number of gout flares, and resolution of tophi in people with gout during the second year of treatment.


Disclosures: L. Stamp, None; C. Frampton, None; M. Morillon, None; W. Taylor, Pfizer (NZ) Ltd, 1; N. Dalbeth, AstraZeneca, 2, JW Pharmaceutical Corporation, 2, PK Med, 2, Horizon, 2, Selecta, 2, Dyve Biosciences, 2, Arthrosi, 2, Amgen, 5; J. Singh, Crealta/Horizon, 2, Medisys, 2, Fidia, 2, PK Med, 2, Two labs Inc, 2, Adept Field Solutions, 2, Clinical Care options, 2, Clearview healthcare partners, 2, Putnam associates, 2, Focus forward, 2, Navigant consulting, 2, Spherix, 2, MedIQ, 2, Jupiter Life Science, 2, UBM LLC, 2, Trio Health, 2, Medscape, 2, WebMD, 2, Practice Point communications, 2, the National Institutes of Health, 2, the American College of Rheumatology, 2, TPT Global Tech, 11, Vaxart pharmaceuticals, 11, Charlotte’s Web Holdings, Inc., 11, Amarin pharmaceuticals, 11, Viking pharmaceuticals, 11, Moderna pharmaceuticals, 11, speaker’s bureau of Simply Speaking, 6, member of the executive of Outcomes Measures in Rheumatology, 4; M. Doherty, None; W. Zhang, Eli Lilly, 1, Regeneron, 1; H. Richardson, None; A. Sarmanova, None; R. Christensen, None.

To cite this abstract in AMA style:

Stamp L, Frampton C, Morillon M, Taylor W, Dalbeth N, Singh J, Doherty M, Zhang W, Richardson H, Sarmanova A, Christensen R. Serum Urate Reduction Is Causally Associated with Flare Outcomes in People with Gout: Evidence for Surrogate Status from a Pooled Analysis of 2 Randomized Trials [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/serum-urate-reduction-is-causally-associated-with-flare-outcomes-in-people-with-gout-evidence-for-surrogate-status-from-a-pooled-analysis-of-2-randomized-trials/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-urate-reduction-is-causally-associated-with-flare-outcomes-in-people-with-gout-evidence-for-surrogate-status-from-a-pooled-analysis-of-2-randomized-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences